Sparks - SIGA Technologies

SIGA Technologies reported a stronger quarter in Q226 (vs Q126), with product sales of $37.9m and total revenues of $41.0m, highlighting continued progress in broadening TPOXX’s international commercial footprint. SIGA delivered c $37m of TPOXX to three customers, including $13m of oral TPOXX to two international customers across Asia-Pacific and Europe, alongside $24m of IV TPOXX to the US Strategic National Stockpile. The international deliveries are particularly encouraging, demonstrating demand for TPOXX beyond the company’s historically important US government business and providing further evidence of geographic diversification. Management noted advanced discussions with another international customer, with deliveries under the contract expected by March 2027. The slower-than-expected US RFP process remains an overhang, although management remains confident in the continued need for smallpox preparedness.

Profitability was strong with Q2 operating income of $13.9m (operating margin of 36.7% on product sales), while net income of $12.5m translated to a net margin of roughly 30%. Although margins moderated year-on-year due to differences in product mix, SIGA’s ability to generate meaningful profitability highlights the attractive economics of the TPOXX franchise. SIGA also remains well capitalised, ending the quarter with $117.6m of cash, providing substantial flexibility to support continued international expansion and future growth opportunities.